|
Real-time Estimate
Cboe BZX
18:15:21 15/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 26.84 USD | -2.47% |
|
-2.32% | +0.86% |
| 08-25 | Deutsche Bank Adjusts ACADIA Pharmaceuticals PT to $38 From $37, Maintains Buy Rating | MT |
| 08-25 | EU Approves Acadia Pharmaceuticals' Rett Syndrome Drug Daybu | MT |
| Market Cap | 4.74B 4.11B 3.88B 3.52B 6.6B 455B 6.65B 46.35B 17.83B 231B 17.81B 17.42B 736B | P/E 2026 * |
45.5x | P/E 2027 * | 32x |
|---|---|---|---|---|---|
| Enterprise Value | 3.73B 3.23B 3.06B 2.77B 5.2B 358B 5.23B 36.49B 14.04B 182B 14.02B 13.71B 579B | EV / Sales 2026 * |
2.93x | EV / Sales 2027 * | 2.45x |
| Free-Float |
99.67% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ACAD | Delayed | |
CBOE
| ACAD | Real-time | |
|
Boerse Muenchen
| DR6 | Real-time | |
|
Mexican S.E.
| ACAD * | End-of-day quote | |
|
Tradegate
| DR6 | Real-time | |
|
Deutsche Boerse AG
| DR6 | Delayed | |
|
Börse Stuttgart
| DR6 | Delayed |
Last Transcript: ACADIA Pharmaceuticals Inc.
| 1 day | -2.47% | ||
| 1 week | -2.32% | ||
| Current month | -6.82% | ||
| 1 month | -7.14% | ||
| 3 months | +26.68% | ||
| 6 months | +25.94% | ||
| Current year | +0.86% |
| 1 week | 26.87 |  | 28.24 |
| 1 month | 26.87 | | 30.96 |
| Current year | 19.89 | | 30.96 |
| 1 year | 19.69 | | 30.96 |
| 3 years | 13.4 | | 32.59 |
| 5 years | 12.24 | | 33.99 |
| 10 years | 12.24 | | 58.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Catherine Adams
CEO | Chief Executive Officer | 55 | 19/09/2024 |
Mark Schneyer
DFI | Director of Finance/CFO | 52 | 09/09/2021 |
Scott Cenci
CTO | Chief Tech/Sci/R&D Officer | - | 03/08/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Laura Brege
BRD | Director/Board Member | 68 | 30/04/2008 |
Stephen Biggar
CHM | Chairman | 55 | 09/06/2016 |
Edmund Harrigan
BRD | Director/Board Member | 73 | 24/11/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 06/08/26 | Exercice | Chief Financial Officer | 42,876 | 0.0250% | ||
| 30/07/26 | Sell | Chief Technology Officer | -16,558 | 0.0097% | ||
| 29/05/26 | Exercice | Director | 41,529 | 0.0243% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.47% | -2.32% | +9.20% | +8.98% | 4.74B | |
| +0.56% | -3.38% | -1.83% | +8.00% | 45.63B | |
| -1.17% | -1.84% | +340.48% | +540.74% | 43.96B | |
| +1.73% | +4.46% | +45.60% | +27.90% | 43.73B | |
| -1.75% | -1.05% | +4.67% | +73.61% | 40.23B | |
| -0.73% | -4.72% | +8.55% | +37.89% | 31.86B | |
| -12.48% | -13.88% | - | - | 17.4B | |
| +3.61% | +4.26% | +24.11% | +120.04% | 16.62B | |
| +1.83% | +3.20% | +16.49% | +32.73% | 14.46B | |
| +0.44% | -2.35% | +80.09% | +31.89% | 13.04B | |
| Average | -1.03% | -1.81% | +58.59% | +97.98% | 27.17B | |
| Weighted average by Cap. | -0.65% | -2.09% | +74.98% | +127.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.27B 1.1B 1.04B 944M 1.77B 122B 1.78B 12.44B 4.79B 61.9B 4.78B 4.67B 197B | 1.43B 1.24B 1.17B 1.06B 1.99B 137B 2.01B 14.01B 5.39B 69.71B 5.38B 5.26B 222B |
| Net income | 106M 91.45M 86.47M 78.29M 147M 10.13B 148M 1.03B 397M 5.13B 397M 388M 16.38B | 156M 135M 128M 116M 218M 15B 219M 1.53B 588M 7.61B 587M 574M 24.26B |
| Net Debt | -1.01B -874M -826M -748M -1.4B -96.78B -1.41B -9.86B -3.79B -49.07B -3.79B -3.71B -157B | -1.24B -1.07B -1.01B -917M -1.72B -119B -1.73B -12.09B -4.65B -60.17B -4.65B -4.54B -192B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/09/26 | US$26.94 | -2.11% | 385,068 |
| 14/09/26 | US$27.52 | -1.11% | 1,628,513 |
| 11/09/26 | US$27.83 | +0.32% | 1,172,902 |
| 10/09/26 | US$27.74 | +0.22% | 1,014,565 |
| 09/09/26 | US$27.68 | +0.36% | 1,293,919 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ACAD Stock
Select your edition
All financial news and data tailored to specific country editions
